1 2478 97 EPIGENETIC UPREGULATION OF CXCL12 EXPRESSION CONTRIBUTES TO THE ACQUISITION AND MAINTENANCE OF MORPHINE-INDUCED CONDITIONED PLACE PREFERENCE. ADDICTION AND REWARDING EFFECT IS A PRIMARY SIDE EFFECT OF MORPHINE, WHICH IS COMMONLY USED TO RELIEVE THE ACUTE OR CHRONIC PAIN. SEVERAL LINES OF EVIDENCE HAVE SUGGESTED THAT INFLAMMATION RESPONSE IN THE VTA CONTRIBUTES TO MORPHINE-INDUCED REWARD (CONDITIONED PLACE PREFERENCE, CPP), WHILE THE MECHANISM ARE POORLY UNDERSTOOD. THE PRESENT STUDY SHOWED THAT REPEATED MORPHINE CONDITIONING PERSISTENTLY INCREASED THE EXPRESSION OF CXCL12 MRNA AND PROTEIN IN VTA. FURTHERMORE, INHIBITION OF CXCL12 PREVENTED THE ACQUISITION AND MAINTENANCE, BUT NOT THE EXPRESSION, OF MORPHINE-INDUCED CPP IN RODENT. IN ADDITION, MOLECULAR ANALYSIS REVEALED THAT MORPHINE CONDITIONING INCREASED THE OCCUPANCY OF P-STAT3 IN THE SPECIFIC BINDING SITE (-1667/-1685) OF CXCL12 PROMOTER REGIONS, AND ENHANCED THE INTERACTION BETWEEN ACETYLTRANSFERASE P300 AND STAT3, AND, HENCE, INDUCED THE HISTONE H4 HYPERACETYLATION IN THE PROMOTER REGION AND FACILITATED THE TRANSCRIPTION AND EXPRESSION OF CXCL12 IN VTA. COLLECTIVELY, THESE RESULTS, FOR THE FIRST TIME, PROVIDED THE EVIDENCE THAT PERSISTED INCREASE OF VTA CXCL12 VIA EPIGENETIC MECHANISM MEDIATED THE ACQUISITION AND MAINTENANCE, BUT NOT THE EXPRESSION, OF MORPHINE CPP. 2018 2 5624 28 SELECTIVE BOOSTING OF TRANSCRIPTIONAL AND BEHAVIORAL RESPONSES TO DRUGS OF ABUSE BY HISTONE DEACETYLASE INHIBITION. HISTONE ACETYLATION AND OTHER MODIFICATIONS OF THE CHROMATIN ARE IMPORTANT REGULATORS OF GENE EXPRESSION AND, CONSEQUENTLY, MAY CONTRIBUTE TO DRUG-INDUCED BEHAVIORS AND NEUROPLASTICITY. EARLIER STUDIES HAVE SHOWN THAT A REDUCTION IN HISTONE DEACETYLASE (HDAC) ACTIVITY RESULTS IN THE ENHANCEMENT OF SOME PSYCHOSTIMULANT-INDUCED BEHAVIORS. IN THIS STUDY, WE EXTEND THOSE SEMINAL FINDINGS BY SHOWING THAT THE ADMINISTRATION OF THE HDAC INHIBITOR SODIUM BUTYRATE ENHANCES MORPHINE-INDUCED LOCOMOTOR SENSITIZATION AND CONDITIONED PLACE PREFERENCE. IN CONTRAST, THIS COMPOUND HAS NO EFFECTS ON THE DEVELOPMENT OF MORPHINE TOLERANCE AND DEPENDENCE. SIMILAR EFFECTS WERE OBSERVED FOR COCAINE AND ETHANOL-INDUCED BEHAVIORS. THESE BEHAVIORAL CHANGES WERE ACCOMPANIED BY A SELECTIVE BOOSTING OF A COMPONENT OF THE TRANSCRIPTIONAL PROGRAM ACTIVATED BY CHRONIC MORPHINE ADMINISTRATION THAT INCLUDED CIRCADIAN CLOCK GENES AND OTHER GENES RELEVANT TO ADDICTIVE BEHAVIOR. OUR RESULTS SUPPORT A SPECIFIC FUNCTION FOR HISTONE ACETYLATION AND THE EPIGENETIC MODULATION OF TRANSCRIPTION AT A REDUCED NUMBER OF BIOLOGICALLY RELEVANT LOCI ON NON-HOMEOSTATIC, LONG-LASTING, DRUG-INDUCED BEHAVIORAL PLASTICITY. 2009 3 2012 27 EPIGENETIC BASIS OF OPIATE SUPPRESSION OF BDNF GENE EXPRESSION IN THE VENTRAL TEGMENTAL AREA. BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) HAS A CRUCIAL ROLE IN MODULATING NEURAL AND BEHAVIORAL PLASTICITY TO DRUGS OF ABUSE. WE FOUND A PERSISTENT DOWNREGULATION OF EXON-SPECIFIC BDNF EXPRESSION IN THE VENTRAL TEGMENTAL AREA (VTA) IN RESPONSE TO CHRONIC OPIATE EXPOSURE, WHICH WAS MEDIATED BY SPECIFIC EPIGENETIC MODIFICATIONS AT THE CORRESPONDING BDNF GENE PROMOTERS. EXPOSURE TO CHRONIC MORPHINE INCREASED STALLING OF RNA POLYMERASE II AT THESE BDNF PROMOTERS IN VTA AND ALTERED PERMISSIVE AND REPRESSIVE HISTONE MODIFICATIONS AND OCCUPANCY OF THEIR REGULATORY PROTEINS AT THE SPECIFIC PROMOTERS. FURTHERMORE, WE FOUND THAT MORPHINE SUPPRESSED BINDING OF PHOSPHO-CREB (CAMP RESPONSE ELEMENT BINDING PROTEIN) TO BDNF PROMOTERS IN VTA, WHICH RESULTED FROM ENRICHMENT OF TRIMETHYLATED H3K27 AT THE PROMOTERS, AND THAT DECREASED NURR1 (NUCLEAR RECEPTOR RELATED-1) EXPRESSION ALSO CONTRIBUTED TO BDNF REPRESSION AND ASSOCIATED BEHAVIORAL PLASTICITY TO MORPHINE. OUR FINDINGS SUGGEST PREVIOUSLY UNKNOWN EPIGENETIC MECHANISMS OF MORPHINE-INDUCED MOLECULAR AND BEHAVIORAL NEUROADAPTATIONS. 2015 4 5485 33 REVERSAL OF COCAINE-CONDITIONED PLACE PREFERENCE THROUGH METHYL SUPPLEMENTATION IN MICE: ALTERING GLOBAL DNA METHYLATION IN THE PREFRONTAL CORTEX. ANALYSIS OF GLOBAL METHYLATION IN CELLS HAS REVEALED CORRELATIONS BETWEEN OVERALL DNA METHYLATION STATUS AND SOME BIOLOGICAL STATES. RECENT STUDIES SUGGEST THAT EPIGENETIC REGULATION THROUGH DNA METHYLATION COULD BE RESPONSIBLE FOR NEUROADAPTATIONS INDUCED BY ADDICTIVE DRUGS. HOWEVER, THERE IS NO INVESTIGATION TO DETERMINE GLOBAL DNA METHYLATION STATUS FOLLOWING REPEATED EXPOSURE TO ADDICTIVE DRUGS. USING MICE CONDITIONED PLACE PREFERENCE (CPP) PROCEDURE, WE MEASURED GLOBAL DNA METHYLATION LEVEL IN THE NUCLEUS ACCUMBENS (NAC) AND THE PREFRONTAL CORTEX (PFC) ASSOCIATED WITH DRUG REWARDING EFFECTS. WE FOUND THAT COCAINE-, BUT NOT MORPHINE- OR FOOD-CPP TRAINING DECREASED GLOBAL DNA METHYLATION IN THE PFC. CHRONIC TREATMENT WITH METHIONINE, A METHYL DONOR, FOR 25 CONSECUTIVE DAYS PRIOR TO AND DURING CPP TRAINING INHIBITED THE ESTABLISHMENT OF COCAINE, BUT NOT MORPHINE OR FOOD CPP. WE ALSO FOUND THAT BOTH MRNA AND PROTEIN LEVEL OF DNMT (DNA METHYTRANSFERASE) 3B IN THE PFC WERE DOWNREGULATED FOLLOWING THE ESTABLISHMENT OF COCAINE CPP, AND THE DOWNREGULATION COULD BE REVERSED BY REPEATED ADMINISTRATION OF METHIONINE. OUR STUDY INDICATES A CRUCIAL ROLE OF GLOBAL PFC DNA HYPOMETHYLATION IN THE REWARDING EFFECTS OF COCAINE. REVERSAL OF GLOBAL DNA HYPOMETHYLATION COULD SIGNIFICANTLY ATTENUATE THE REWARDING EFFECTS INDUCED BY COCAINE. OUR RESULTS SUGGEST THAT METHIONINE MAY HAVE BECOME A POTENTIAL THERAPEUTIC TARGET TO TREAT COCAINE ADDICTION. 2012 5 4173 27 MELATONIN INDUCES HISTONE HYPERACETYLATION IN THE RAT BRAIN. WE HAVE REPORTED THAT MELATONIN INDUCES HISTONE HYPERACETYLATION IN MOUSE NEURAL STEM CELLS, SUGGESTING AN EPIGENETIC ROLE FOR THIS PLEIOTROPIC HORMONE. TO SUPPORT SUCH A ROLE, IT IS NECESSARY TO DEMONSTRATE THAT MELATONIN PRODUCES SIMILAR EFFECTS IN VIVO. HISTONE ACETYLATION, FOLLOWING CHRONIC TREATMENT WITH MELATONIN (4MUG/ML IN DRINKING WATER FOR 17 DAYS), WAS EXAMINED BY WESTERN BLOTTING IN SELECTED RAT BRAIN REGIONS. MELATONIN INDUCED SIGNIFICANT INCREASES IN HISTONE H3 AND HISTONE H4 ACETYLATION IN THE HIPPOCAMPUS. HISTONE H4 WAS ALSO HYPERACETYLATED IN THE STRIATUM, BUT THERE WERE NO SIGNIFICANT CHANGES IN HISTONE H3 ACETYLATION IN THIS BRAIN REGION. NO SIGNIFICANT CHANGES IN THE ACETYLATION OF EITHER HISTONE H3 OR H4 WERE OBSERVED IN THE MIDBRAIN AND CEREBELLUM. AN EXAMINATION OF KINASE ACTIVATION, WHICH MAY BE RELATED TO THESE CHANGES, REVEALED THAT MELATONIN TREATMENT INCREASED THE LEVELS OF PHOSPHO-ERK (EXTRACELLULAR SIGNAL-REGULATED KINASE) IN THE HIPPOCAMPUS AND STRIATUM, BUT PHOSPHO-AKT (PROTEIN KINASE B) LEVELS WERE UNCHANGED. THESE FINDINGS SUGGEST THAT CHROMATIN REMODELING AND ASSOCIATED CHANGES IN THE EPIGENETIC REGULATION OF GENE EXPRESSION UNDERLIE THE MULTIPLE PHYSIOLOGICAL EFFECTS OF MELATONIN. 2013 6 2280 34 EPIGENETIC REGULATION IN DRUG ADDICTION. THE INTERACTION BETWEEN ENVIRONMENTAL SIGNALS AND GENES HAS NOW TAKEN ON A CLEAR MOLECULAR FORM AS DEMONSTRATED BY STABLE CHANGES IN CHROMATIN STRUCTURE. THESE CHANGES OCCUR THROUGH ACTIVATION OR REPRESSION OF SPECIFIC GENE PROGRAMMES BY A COMBINATION OF CHROMATIN REMODELLING, ACTIVATION AND ENZYMATIC MODIFICATION OF DNA AND HISTONES AS WELL AS NUCLEOSOMAL SUBUNIT EXCHANGE. RECENT RESEARCH INVESTIGATING THE MOLECULAR MECHANISMS CONTROLLING DRUG-INDUCED TRANSCRIPTIONAL, BEHAVIOURAL AND SYNAPTIC ACTIVITY HAS SHOWN A DIRECT ROLE FOR CHROMATIN REMODELLING--TERMED AS EPIGENETIC REGULATION--OF NEURONAL GENE PROGRAMMES AND SUBSEQUENT ADDICTIVE BEHAVIOUR ARISING FROM IT. RECENT DATA SUGGEST THAT REPEATED EXPOSURE TO CERTAIN DRUGS PROMOTES CHANGES IN LEVELS OF HISTONE ACETYLATION, PHOSPHORYLATION AND METHYLATION, TOGETHER WITH ALTERATIONS IN DNA METHYLATION LEVELS IN THE NEURONS OF THE BRAIN REWARD CENTRE, LOCALISED IN THE NUCLEUS ACCUMBENS (NAC) REGION OF THE LIMBIC SYSTEM. THE COMBINATION OF ACETYLATING, PHOSPHORYLATING AND METHYLATING H3 AND H4 HISTONE TAILS ALTER CHROMATIN COMPACTION THEREBY PROMOTING ALTERED LEVELS OF CELLULAR GENE EXPRESSION. HISTONE MODIFICATIONS, WHICH WEAKEN HISTONE INTERACTION WITH DNA OR THAT PROMOTE RECRUITMENT OF TRANSCRIPTIONAL ACTIVATING COMPLEXES, CORRELATE WITH PERMISSIVE GENE EXPRESSION. HISTONE DEACETYLATION, (WHICH STRENGTHEN HISTONE: DNA CONTACTS), OR HISTONE METHYLATION, (WHICH RECRUITS REPRESSIVE COMPLEXES TO CHROMATIN), PROMOTE A STATE OF TRANSCRIPTIONAL REPRESSION. USING ANIMAL MODELS, ACUTE COCAINE TREATMENT INCREASES H4 ACETYLATION AT ACUTELY REGULATED GENE PROMOTERS, WHEREAS H3 ACETYLATION APPEARS TO PREDOMINATE AT CHRONICALLY INDUCED PROMOTERS. CHRONIC COCAINE AND ALCOHOL TREATMENT ACTIVATE AND REPRESS MANY GENES SUCH AS FOSB, CDK5, AND BDNF, WHERE THEIR DYSREGULATION, AT THE CHROMATIN LEVEL, CONTRIBUTE TO THE DEVELOPMENT AND MAINTENANCE OF ADDICTION. FOLLOWING DRUG EXPOSURE, IT IS STILL UNKNOWN, HOWVER, HOW LONG THESE CHANGES IN CHROMATIN STRUCTURE PERSIST IN AFFECTING NEURONAL FUNCTION, BUT SOME DO SO FOR LIFE. 2012 7 4498 31 MORPHINE REGULATES ARGONAUTE 2 AND TH EXPRESSION AND ACTIVITY BUT NOT MIR-133B IN MIDBRAIN DOPAMINERGIC NEURONS. EPIGENETIC CHANGES SUCH AS MICRORNAS (MIRS)/AGO2-INDUCED GENE SILENCING REPRESENT COMPLEX MOLECULAR SIGNATURE THAT REGULATE CELLULAR PLASTICITY. RECENT STUDIES SHOWED INVOLVEMENT OF MIRS AND AGO2 IN DRUG ADDICTION. IN THIS STUDY, WE SHOW THAT CHANGES IN GENE EXPRESSION INDUCED BY MORPHINE AND MORPHINE WITHDRAWAL OCCUR WITH CONCOMITANT EPIGENETIC MODIFICATIONS IN THE MESOLIMBIC DOPAMINERGIC (DA) PATHWAY [VENTRAL TEGMENTAL AREA (VTA)/NUCLEUS ACCUMBENS (NAC) SHELL], WHICH IS CRITICALLY INVOLVED IN DRUG-INDUCED DEPENDENCE. WE FOUND THAT ACUTE OR CHRONIC MORPHINE ADMINISTRATION AS WELL AS MORPHINE WITHDRAWAL DID NOT MODIFY MIR-133B MESSENGER RNA (MRNA) EXPRESSION IN THE VTA, WHEREAS AGO2 PROTEIN LEVELS WERE DECREASED AND INCREASED IN MORPHINE-DEPENDENT RATS AND AFTER MORPHINE WITHDRAWAL, RESPECTIVELY. THESE CHANGES WERE PARALLELED WITH ENHANCED AND DECREASED NAC TYROSINE HYDROXYLASE (TH) PROTEIN (AN EARLY DA MARKER) IN MORPHINE-DEPENDENT RATS AND AFTER WITHDRAWAL, RESPECTIVELY. WE ALSO OBSERVED CHANGES IN TH MRNA EXPRESSION IN THE VTA THAT COULD BE RELATED TO AGO2-INDUCED TRANSLATIONAL REPRESSION OF TH MRNA DURING MORPHINE WITHDRAWAL. HOWEVER, THE VTA NUMBER OF TH-POSITIVE NEURONS SUFFERED NO ALTERATIONS AFTER THE DIFFERENT TREATMENT. ACUTE MORPHINE ADMINISTRATION PRODUCED A MARKED INCREASE IN TH ACTIVITY AND DA TURNOVER IN THE NAC (SHELL). IN CONTRAST, PRECIPITATED MORPHINE WITHDRAWAL DECREASED TH ACTIVATION AND DID NOT CHANGE DA TURNOVER. THESE FINDINGS PROVIDE NEW INFORMATION INTO THE POSSIBLE CORRELATION BETWEEN AGO2/MIRS COMPLEX REGULATION AND DA NEURONS PLASTICITY DURING OPIATE ADDICTION. 2015 8 4497 33 MORPHINE LEADS TO GLOBAL GENOME CHANGES IN H3K27ME3 LEVELS VIA A POLYCOMB REPRESSIVE COMPLEX 2 (PRC2) SELF-REGULATORY MECHANISM IN MESCS. BACKGROUND: ENVIRONMENTALLY INDUCED EPIGENETIC CHANGES CAN LEAD TO HEALTH PROBLEMS OR DISEASE, BUT THE MECHANISMS INVOLVED REMAIN UNCLEAR. MORPHINE CAN PASS THROUGH THE PLACENTAL BARRIER LEADING TO ABNORMAL EMBRYO DEVELOPMENT. HOWEVER, THE MECHANISM BY WHICH MORPHINE CAUSES THESE EFFECTS AND HOW THEY SOMETIMES PERSIST INTO ADULTHOOD IS NOT WELL KNOWN. TO UNRAVEL THE MORPHINE-INDUCED CHROMATIN ALTERATIONS INVOLVED IN ABERRANT EMBRYO DEVELOPMENT, WE EXPLORED THE ROLE OF THE H3K27ME3/PRC2 REPRESSIVE COMPLEX IN GENE EXPRESSION AND ITS TRANSMISSION ACROSS CELLULAR GENERATIONS IN RESPONSE TO MORPHINE. RESULTS: USING MOUSE EMBRYONIC STEM CELLS AS A MODEL SYSTEM, WE FOUND THAT CHRONIC MORPHINE TREATMENT INDUCES A GLOBAL DOWNREGULATION OF THE HISTONE MODIFICATION H3K27ME3. CONVERSELY, CHIP-SEQ SHOWED A REMARKABLE INCREASE IN H3K27ME3 LEVELS AT SPECIFIC GENOMIC SITES, PARTICULARLY PROMOTERS, DISRUPTING SELECTIVE TARGET GENES RELATED TO EMBRYO DEVELOPMENT, CELL CYCLE AND METABOLISM. THROUGH A SELF-REGULATORY MECHANISM, MORPHINE DOWNREGULATED THE TRANSCRIPTION OF PRC2 COMPONENTS RESPONSIBLE FOR H3K27ME3 BY ENRICHING HIGH H3K27ME3 LEVELS AT THE PROMOTER REGION. DOWNREGULATION OF PRC2 COMPONENTS PERSISTED FOR AT LEAST 48 H (4 CELL CYCLES) FOLLOWING MORPHINE REMOVAL, THOUGH PROMOTER H3K27ME3 LEVELS RETURNED TO CONTROL LEVELS. CONCLUSIONS: MORPHINE INDUCES TARGETING OF THE PRC2 COMPLEX TO SELECTED PROMOTERS, INCLUDING THOSE OF PRC2 COMPONENTS, LEADING TO CHARACTERISTIC CHANGES IN GENE EXPRESSION AND A GLOBAL REDUCTION IN H3K27ME3. FOLLOWING MORPHINE REMOVAL, ENHANCED PROMOTER H3K27ME3 LEVELS REVERT TO NORMAL SOONER THAN GLOBAL H3K27ME3 OR PRC2 COMPONENT TRANSCRIPT LEVELS. WE SUGGEST THAT H3K27ME3 IS INVOLVED IN INITIATING MORPHINE-INDUCED CHANGES IN GENE EXPRESSION, BUT NOT IN THEIR MAINTENANCE. MODEL OF POLYCOMB REPRESSIVE COMPLEX 2 (PRC2) AND H3K27ME3 ALTERATIONS INDUCED BY CHRONIC MORPHINE EXPOSURE. MORPHINE INDUCES H3K27ME3 ENRICHMENT AT PROMOTERS OF GENES ENCODING CORE MEMBERS OF THE PRC2 COMPLEX AND IS ASSOCIATED WITH THEIR TRANSCRIPTIONAL DOWNREGULATION. 2020 9 1238 22 CURCUMIN BLOCKS CHRONIC MORPHINE ANALGESIC TOLERANCE AND BRAIN-DERIVED NEUROTROPHIC FACTOR UPREGULATION. THIS STUDY WAS CARRIED OUT BASED ON THE ASSUMPTION THAT BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) MAY COUNTERBALANCE THE ACTION OF MORPHINE IN THE BRAIN. MORPHINE ANALGESIC TOLERANCE AFTER DAILY ADMINISTRATIONS FOR SIX DAYS WAS BLOCKED BY INTRACEREBROVENTRICULAR INJECTION OF ANTI-BDNF IGG ON DAY 5, BUT NOT BY ADMINISTRATIONS ON DAYS 1-4. CHRONIC MORPHINE TREATMENT SIGNIFICANTLY INCREASED THE EXPRESSION OF EXON I AND IV BDNF TRANSCRIPTS, INDICATING DIFFERENTIAL REGULATION OF BDNF GENE EXPRESSION. DAILY ADMINISTRATION OF THE CREB-BINDING PROTEIN INHIBITOR CURCUMIN ABOLISHED THE UPREGULATION OF BDNF TRANSCRIPTION AND MORPHINE ANALGESIC TOLERANCE. THESE RESULTS SUGGEST THAT CURCUMIN MIGHT BE A PROMISING ADJUVANT TO REDUCE MORPHINE ANALGESIC TOLERANCE, AND THAT EPIGENETIC CONTROL COULD BE A NEW STRATEGY USEFUL FOR THE CONTROL OF THIS PROBLEM. 2009 10 3194 28 HDAC INHIBITORS ATTENUATE THE DEVELOPMENT OF HYPERSENSITIVITY IN MODELS OF NEUROPATHIC PAIN. HISTONE DEACETYLASE INHIBITORS (HDACIS) INTERFERE WITH THE EPIGENETIC PROCESS OF HISTONE ACETYLATION AND ARE KNOWN TO HAVE ANALGESIC PROPERTIES IN MODELS OF CHRONIC INFLAMMATORY PAIN. THE AIM OF THIS STUDY WAS TO DETERMINE WHETHER THESE COMPOUNDS COULD ALSO AFFECT NEUROPATHIC PAIN. DIFFERENT CLASS I HDACIS WERE DELIVERED INTRATHECALLY INTO RAT SPINAL CORD IN MODELS OF TRAUMATIC NERVE INJURY AND ANTIRETROVIRAL DRUG-INDUCED PERIPHERAL NEUROPATHY (STAVUDINE, D4T). MECHANICAL AND THERMAL HYPERSENSITIVITY WAS ATTENUATED BY 40% TO 50% AS A RESULT OF HDACI TREATMENT, BUT ONLY IF STARTED BEFORE ANY INSULT. THE DRUGS GLOBALLY INCREASED HISTONE ACETYLATION IN THE SPINAL CORD, BUT APPEARED TO HAVE NO MEASURABLE EFFECTS IN RELEVANT DORSAL ROOT GANGLIA IN THIS TREATMENT PARADIGM, SUGGESTING THAT ANY POTENTIAL MECHANISM SHOULD BE SOUGHT IN THE CENTRAL NERVOUS SYSTEM. MICROARRAY ANALYSIS OF DORSAL CORD RNA REVEALED THE SIGNATURE OF THE SPECIFIC COMPOUND USED (MS-275) AND SUGGESTED THAT ITS MAIN EFFECT WAS MEDIATED THROUGH HDAC1. TAKEN TOGETHER, THESE DATA SUPPORT A ROLE FOR HISTONE ACETYLATION IN THE EMERGENCE OF NEUROPATHIC PAIN. 2013 11 882 38 CHRONIC COCAINE-INDUCED H3 ACETYLATION AND TRANSCRIPTIONAL ACTIVATION OF CAMKIIALPHA IN THE NUCLEUS ACCUMBENS IS CRITICAL FOR MOTIVATION FOR DRUG REINFORCEMENT. THE REGULATION OF GENE EXPRESSION IN THE BRAIN REWARD REGIONS IS KNOWN TO CONTRIBUTE TO THE PATHOGENESIS AND PERSISTENCE OF DRUG ADDICTION. INCREASING EVIDENCE SUGGESTS THAT THE REGULATION OF GENE TRANSCRIPTION IS MEDIATED BY EPIGENETIC MECHANISMS THAT ALTER THE CHROMATIN STRUCTURE AT SPECIFIC GENE PROMOTERS. TO BETTER UNDERSTAND THE INVOLVEMENT OF EPIGENETIC REGULATION IN DRUG REINFORCEMENT PROPERTIES, RATS WERE SUBJECTED TO COCAINE SELF-ADMINISTRATION PARADIGM. DAILY HISTONE DEACETYLASE (HDAC) INHIBITOR INFUSIONS IN THE SHELL OF THE NUCLEUS ACCUMBENS (NAC) CAUSED AN UPWARD SHIFT IN THE DOSE-RESPONSE CURVE UNDER FIXED-RATIO SCHEDULE AND INCREASED THE BREAK POINT UNDER PROGRESSIVE-RATIO SCHEDULE, INDICATING ENHANCED MOTIVATION FOR SELF-ADMINISTERED DRUG. THE EFFECT OF THE HDAC INHIBITOR IS ATTRIBUTED TO THE INCREASED ELEVATION OF HISTONE ACETYLATION INDUCED BY CHRONIC, BUT NOT ACUTE, COCAINE EXPERIENCE. IN CONTRAST, NEUTRALIZING THE CHRONIC COCAINE-INDUCED INCREASE IN HISTONE MODIFICATION BY THE BILATERAL OVEREXPRESSION OF HDAC4 IN THE NAC SHELL REDUCED DRUG MOTIVATION. THE ASSOCIATION BETWEEN THE MOTIVATION FOR COCAINE AND THE TRANSCRIPTIONAL ACTIVATION OF ADDICTION-RELATED GENES BY H3 ACETYLATION IN THE NAC SHELL WAS ANALYZED. AMONG THE GENES ACTIVATED BY CHRONIC COCAINE EXPERIENCES, THE EXPRESSION OF CAMKIIALPHA, BUT NOT CAMKIIBETA, CORRELATED POSITIVELY WITH MOTIVATION FOR THE DRUG. LENTIVIRUS-MEDIATED SHRNA KNOCKDOWN EXPERIMENTS SHOWED THAT CAMKIIALPHA, BUT NOT CAMKIIBETA, IN THE NAC SHELL IS ESSENTIAL FOR THE MAINTENANCE OF MOTIVATION TO SELF-ADMINISTERED COCAINE. THESE FINDINGS SUGGEST THAT CHRONIC DRUG-USE-INDUCED TRANSCRIPTIONAL ACTIVATION OF GENES, SUCH AS CAMKIIALPHA, MODULATED BY H3 ACETYLATION IN THE NAC IS A CRITICAL REGULATORY MECHANISM UNDERLYING MOTIVATION FOR DRUG REINFORCEMENT. 2010 12 6801 37 [EPIGENETIC MECHANISMS AND ALCOHOL USE DISORDERS: A POTENTIAL THERAPEUTIC TARGET]. ALCOHOL USE DISORDER IS A DEVASTATING ILLNESS WITH A PROFOUND HEALTH IMPACT, AND ITS DEVELOPMENT IS DEPENDENT ON BOTH GENETIC AND ENVIRONMENTAL FACTORS. THIS DISEASE OCCURS OVER TIME AND REQUIRES CHANGES IN BRAIN GENE EXPRESSION. THERE IS CONVERGING EVIDENCE SUGGESTING THAT THE EPIGENETIC PROCESSES MAY PLAY A ROLE IN THE ALCOHOL-INDUCED GENE REGULATIONS AND BEHAVIOR SUCH AS THE INTERVENTION OF DNA METHYLATION AND HISTONE ACETYLATION. HISTONE ACETYLATION, LIKE HISTONE METHYLATION, IS A HIGHLY DYNAMIC PROCESS REGULATED BY TWO CLASSES OF ENZYMES: HISTONE ACETYLTRANSFERASES AND HISTONE DEACETYLASES (HDACS). TO DATE, 18 HUMAN HDAC ISOFORMS HAVE BEEN CHARACTERIZED, AND BASED ON THEIR SEQUENCE HOMOLOGIES AND COFACTOR DEPENDENCIES, THEY HAVE BEEN PHYLOGENETICALLY CATEGORIZED INTO 4 MAIN CLASSES: CLASSES I, II (A AND B), III, AND IV. IN THE BRAIN, EXPRESSION OF THE DIFFERENT CLASSES OF HDACS VARIES BETWEEN CELL TYPES AND ALSO IN THEIR SUBCELLULAR LOCALIZATION (NUCLEUS AND/OR CYTOSOL). FURTHERMORE, WE RECENTLY SHOWED THAT A SINGLE ETHANOL EXPOSURE INHIBITS HDAC ACTIVITY AND INCREASES BOTH H3 AND H4 HISTONE ACETYLATION WITHIN THE AMYGDALA OF RATS. IN THE BRAIN OF ALCOHOLIC PATIENTS, ETHANOL HAS BEEN SHOWN TO INDUCE HISTONE-RELATED AND DNA METHYLATION EPIGENETIC CHANGES IN SEVERAL REWARD REGIONS INVOLVED IN REWARD PROCESSES SUCH AS HIPPOCAMPUS, PREFRONTAL CORTEX, AND AMYGDALA. WE RECENTLY DEMONSTRATED ALTERATION OF HISTONE H3 ACETYLATION LEVELS IN SEVERAL BRAIN REGIONS FROM THE REWARD CIRCUIT OF RATS MADE DEPENDENT TO ALCOHOL AFTER CHRONIC AND INTERMITTENT EXPOSURE TO ETHANOL VAPOR. IN NEURONAL CELL LINE CULTURE, ETHANOL WAS SHOWN TO INDUCE HDAC EXPRESSION. IN MOUSE AND RAT BRAIN, NUMEROUS STUDIES REPORTED EPIGENETIC ALTERATIONS FOLLOWING ETHANOL EXPOSURE. WE ALSO DEMONSTRATED THAT BOTH THE EXPRESSION OF GENES AND THE ACTIVITY OF ENZYMES INVOLVED IN EPIGENETIC MECHANISMS ARE CHANGED AFTER REPEATED ADMINISTRATIONS OF ETHANOL IN MICE SENSITIZED TO THE MOTOR STIMULANT EFFECT OF ETHANOL (A MODEL OF DRUG-INDUCED NEUROPLASTICITY). NUMEROUS STUDIES HAVE SHOWN THAT HDAC INHIBITORS ARE ABLE TO COUNTER ETHANOL-INDUCED BEHAVIORS AND THE ETHANOL-INDUCED CHANGES IN THE LEVELS OF HDAC AND/OR LEVELS OF ACETYLATED HDAC. FOR EXAMPLE, TRICHOSTATIN A (TSA) TREATMENT CAUSED THE REVERSAL OF ETHANOL-INDUCED TOLERANCE, ANXIETY, AND ETHANOL DRINKING BY INHIBITING HDAC ACTIVITY, THEREBY INCREASING HISTONE ACETYLATION IN THE AMYGDALA OF RATS. ANOTHER STUDY DEMONSTRATED THAT TSA PREVENTED THE DEVELOPMENT OF ETHANOL WITHDRAWAL INDUCED ANXIETY IN RATS BY RESCUING DEFICITS IN HISTONE ACETYLATION INDUCED BY INCREASED HDAC ACTIVITY IN THE AMYGDALA. WE HAVE DEMONSTRATED THAT TREATMENT WITH THE HDAC INHIBITOR SODIUM BUTYRATE BLOCKS BOTH THE DEVELOPMENT AND THE EXPRESSION OF ETHANOL-INDUCED BEHAVIORAL SENSITIZATION IN MICE. IN THIS CONTEXT, CONVERGING EVIDENCE INDICATES THAT HDAC INHIBITORS COULD BE USEFUL IN COUNTERACTING ETHANOL-INDUCED GENE REGULATIONS VIA EPIGENETIC MECHANISMS, THAT IS, HDAC INHIBITORS COULD AFFECT DIFFERENT ACETYLATION SITES AND MAY ALSO ALTER THE EXPRESSION OF DIFFERENT GENES THAT COULD IN TURN COUNTERACT THE EFFECT OF ETHANOL. RECENT WORK IN RODENTS HAS SHOWN THAT SYSTEMIC ADMINISTRATION OF PAN HDAC CLASS I AND II INHIBITORS, TSA AND N-HYDROXY-N-PHENYL-OCTANEDIAMIDE [SUBEROYLANILIDE HYDROXAMIC ACID] (SAHA), AND OF THE MORE SELECTIVE INHIBITOR (MAINLY HDAC1 AND HDAC9) MS-275, DECREASE BINGE-LIKE ALCOHOL DRINKING IN MICE. SAHA SELECTIVELY REDUCED ETHANOL OPERANT SELF-ADMINISTRATION AND SEEKING IN RATS. OUR PREVIOUS STUDY REVEALED THAT MS-275 STRONGLY DECREASED OPERANT ETHANOL SELF-ADMINISTRATION IN ALCOHOL-DEPENDENT RATS WHEN ADMINISTERED 30 MINUTES BEFORE THE SESSION AT THE SECOND DAY OF INJECTION. WE ALSO DEMONSTRATED THAT INTRA-CEREBRO-VENTRICULAR INFUSION OF MS-275 INCREASES ACETYLATION OF HISTONE 4 WITHIN THE NUCLEUS ACCUMBENS AND THE DORSOLATERAL STRIATUM, ASSOCIATED TO A DECREASE IN ETHANOL SELF-ADMINISTRATION BY ABOUT 75%. MS-275 ALSO DIMINISHED BOTH THE MOTIVATION TO CONSUME ETHANOL (25% DECREASE), RELAPSE (BY ABOUT 50%) AND POSTPONED REACQUISITION AFTER ABSTINENCE. BOTH LITERATURE AND SEVERAL OF OUR STUDIES STRONGLY SUPPORT THE POTENTIAL THERAPEUTIC INTEREST OF TARGETING EPIGENETIC MECHANISMS IN EXCESSIVE ALCOHOL DRINKING AND STRENGTHEN THEINTEREST OF FOCUSING ON SPECIFIC ISOFORMS OF HISTONE DEACETYLASES. 2017 13 345 32 ALTERED BRAIN EXPRESSION OF DNA METHYLATION AND HYDROXYMETHYLATION EPIGENETIC ENZYMES IN A RAT MODEL OF NEUROPATHIC PAIN. THE ROLE OF EPIGENETICS IN CHRONIC PAIN AT THE SUPRASPINAL LEVEL IS YET TO BE FULLY CHARACTERIZED. DNA HISTONE METHYLATION IS CRUCIALLY REGULATED BY DE NOVO METHYLTRANSFERASES (DNMT1-3) AND TEN-ELEVEN TRANSLOCATION DIOXYGENASES (TET1-3). EVIDENCE HAS SHOWN THAT METHYLATION MARKERS ARE ALTERED IN DIFFERENT CNS REGIONS RELATED TO NOCICEPTION, NAMELY THE DORSAL ROOT GANGLIA, THE SPINAL CORD, AND DIFFERENT BRAIN AREAS. DECREASED GLOBAL METHYLATION WAS FOUND IN THE DRG, THE PREFRONTAL CORTEX, AND THE AMYGDALA, WHICH WAS ASSOCIATED WITH DECREASED DNMT1/3A EXPRESSION. IN CONTRAST, INCREASED METHYLATION LEVELS AND MRNA LEVELS OF TET1 AND TET3 WERE LINKED TO AUGMENTED PAIN HYPERSENSITIVITY AND ALLODYNIA IN INFLAMMATORY AND NEUROPATHIC PAIN MODELS. SINCE EPIGENETIC MECHANISMS MAY BE RESPONSIBLE FOR THE REGULATION AND COORDINATION OF VARIOUS TRANSCRIPTIONAL MODIFICATIONS DESCRIBED IN CHRONIC PAIN STATES, WITH THIS STUDY, WE AIMED TO EVALUATE THE FUNCTIONAL ROLE OF TET1-3 AND DNMT1/3A GENES IN NEUROPATHIC PAIN IN SEVERAL BRAIN AREAS. IN A SPARED NERVE INJURY RAT MODEL OF NEUROPATHIC PAIN, 21 DAYS AFTER SURGERY, WE FOUND INCREASED TET1 EXPRESSION IN THE MEDIAL PREFRONTAL CORTEX AND DECREASED EXPRESSION IN THE CAUDATE-PUTAMEN AND THE AMYGDALA; TET2 WAS UPREGULATED IN THE MEDIAL THALAMUS; TET3 MRNA LEVELS WERE REDUCED IN THE MEDIAL PREFRONTAL CORTEX AND THE CAUDATE-PUTAMEN; AND DNMT1 WAS DOWNREGULATED IN THE CAUDATE-PUTAMEN AND THE MEDIAL THALAMUS. NO STATISTICALLY SIGNIFICANT CHANGES IN EXPRESSION WERE OBSERVED WITH DNMT3A. OUR RESULTS SUGGEST A COMPLEX FUNCTIONAL ROLE FOR THESE GENES IN DIFFERENT BRAIN AREAS IN THE CONTEXT OF NEUROPATHIC PAIN. THE NOTION OF DNA METHYLATION AND HYDROXYMETHYLATION BEING CELL-TYPE SPECIFIC AND NOT TISSUE SPECIFIC, AS WELL AS THE POSSIBILITY OF CHRONOLOGICALLY DIFFERENTIAL GENE EXPRESSION AFTER THE ESTABLISHMENT OF NEUROPATHIC OR INFLAMMATORY PAIN MODELS, OUGHT TO BE ADDRESSED IN FUTURE STUDIES. 2023 14 2253 32 EPIGENETIC MODULATION OF WNT SIGNALING CONTRIBUTES TO NEUROPATHIC PAIN IN RATS. PREVIOUS STUDIES HAVE DEMONSTRATED THAT THE WNT/BETA?CATENIN SIGNALING PATHWAY IS CRITICAL TO THE INDUCTION AND MAINTENANCE OF CHRONIC NEUROPATHIC PAIN CAUSED BY PERIPHERAL INFLAMMATION AND NERVE DAMAGE. EMERGING EVIDENCE FROM RECENT STUDIES SUGGESTS THAT EPIGENETIC MECHANISMS MAY ALSO BE CRITICAL TO THE PATHOGENESIS OF CHRONIC PAIN. THE PRESENT STUDY AIMED TO ELUCIDATE THE EPIGENETIC MECHANISMS UNDERLYING ALTERED WNT SIGNALING AND THEIR INVOLVEMENT IN CCI?INDUCED NEUROPATHIC PAIN IN RAT SCIATIC NERVES. THE RESULTS OF THE PRESENT STUDY DEMONSTRATED A SIGNIFICANT INCREASE IN THE EXPRESSION LEVELS OF WNT3A IN THE DORSAL HORN OF THE RATS WITH CCI. IN ADDITION, A SIGNIFICANT INCREASE IN HISTONE H3 ACETYLATION, AND A SIGNIFICANT DECREASE IN CYTOSINE METHYLATION IN THE PROMOTER REGION OF WNT3A WAS OBSERVED IN THE DORSAL HORN OF THE RATS WITH CCI. INTRATHECAL APPLICATION OF XAV939, WHICH ACTS AS AN INHIBITOR OF WNT SIGNALING, SIGNIFICANTLY DECREASED THE EXPRESSION LEVELS OF ACTIVE BETA?CATENIN, AND ATTENUATED THE RAT BEHAVIORAL RESPONSES TO THERMAL AND MECHANICAL PAIN STIMULI. THESE RESULTS SUGGEST THAT THE EPIGENETIC UPREGULATION OF WNT3A IN THE DORSAL HORN CONTRIBUTES TO THE MAINTENANCE OF PAIN?INDUCED BEHAVIOR IN RATS WITH CCI. 2015 15 4150 33 MECHANISTIC INSIGHTS INTO EPIGENETIC MODULATION OF ETHANOL CONSUMPTION. THERE IS GROWING EVIDENCE THAT SMALL-MOLECULE INHIBITORS OF EPIGENETIC MODULATORS, SUCH AS HISTONE DEACETYLASES (HDAC) AND DNA METHYLTRANSFERASES (DNMT), CAN REDUCE VOLUNTARY ETHANOL CONSUMPTION IN ANIMAL MODELS, BUT MOLECULAR AND CELLULAR PROCESSES UNDERLYING THIS BEHAVIORAL EFFECT ARE POORLY UNDERSTOOD. WE USED C57BL/6J MALE MICE TO INVESTIGATE THE EFFECTS OF TWO FDA-APPROVED DRUGS, DECITABINE (A DNMT INHIBITOR) AND SAHA (AN HDAC INHIBITOR), ON ETHANOL CONSUMPTION USING TWO TESTS: BINGE-LIKE DRINKING IN THE DARK (DID) AND CHRONIC INTERMITTENT EVERY OTHER DAY (EOD) DRINKING. DECITABINE BUT NOT SAHA REDUCED ETHANOL CONSUMPTION IN BOTH TESTS. WE FURTHER INVESTIGATED DECITABINE'S EFFECTS ON THE BRAIN'S REWARD PATHWAY BY GENE EXPRESSION PROFILING IN THE VENTRAL TEGMENTAL AREA (VTA), USING RNA SEQUENCING AND ELECTROPHYSIOLOGICAL RECORDINGS FROM VTA DOPAMINERGIC NEURONS. DECITABINE-INDUCED DECREASES IN EOD DRINKING WERE ASSOCIATED WITH GLOBAL CHANGES IN GENE EXPRESSION, IMPLICATING REGULATION OF CEREBRAL BLOOD FLOW, EXTRACELLULAR MATRIX ORGANIZATION, AND NEUROIMMUNE FUNCTIONS IN DECITABINE ACTIONS. IN ADDITION, AN IN VIVO ADMINISTRATION OF DECITABINE SHORTENED ETHANOL-INDUCED EXCITATION OF VTA DOPAMINERGIC NEURONS IN VITRO, SUGGESTING THAT DECITABINE REDUCES ETHANOL DRINKING VIA CHANGES IN THE REWARD PATHWAY. TAKEN TOGETHER, OUR DATA SUGGEST A CONTRIBUTION OF BOTH NEURONAL AND NON-NEURONAL MECHANISMS IN THE VTA IN THE REGULATION OF ETHANOL CONSUMPTION. DECITABINE AND OTHER EPIGENETIC COMPOUNDS HAVE BEEN APPROVED FOR CANCER TREATMENT, AND UNDERSTANDING THEIR MECHANISMS OF ACTIONS IN THE BRAIN MAY ASSIST IN REPURPOSING THESE DRUGS AND DEVELOPING NOVEL THERAPIES FOR CENTRAL DISORDERS, INCLUDING DRUG ADDICTION. 2017 16 3319 24 HISTONE ACETYLATION AND HISTONE DEACETYLATION IN NEUROPATHIC PAIN: AN UNRESOLVED PUZZLE? CHRONIC PAIN IS BROADLY CLASSIFIED INTO SOMATIC, VISCERAL OR NEUROPATHIC PAIN DEPENDING UPON THE LOCATION AND EXTENT OF PAIN PERCEPTION. EVIDENCES FROM DIFFERENT ANIMAL STUDIES SUGGEST THAT INFLAMMATORY OR NEUROPATHIC PAIN IS ASSOCIATED WITH ALTERED ACETYLATION AND DEACETYLATION OF HISTONE PROTEINS, WHICH RESULT IN ABNORMAL TRANSCRIPTION OF NOCICEPTIVE PROCESSING GENES. THERE HAVE BEEN A NUMBER OF STUDIES INDICATING THAT NERVE INJURY UP-REGULATES HISTONE DEACETYLASE ENZYMES, WHICH LEADS TO INCREASED HISTONE DEACETYLATION AND INDUCE CHRONIC PAIN. TREATMENT WITH HISTONE DEACETYLASE INHIBITORS RELIEVES PAIN BY NORMALIZING NERVE INJURY-INDUCED DOWN REGULATION OF METABOTROPIC GLUTAMATE RECEPTORS, GLUTAMATE TRANSPORTERS, GLUTAMIC ACID DECARBOXYLASE 65, NEURON RESTRICTIVE SILENCER FACTOR AND SERUM AND GLUCOCORTICOID INDUCIBLE KINASE 1. ON THE OTHER HAND, A FEW STUDIES REFER TO INCREASED EXPRESSION OF HISTONE ACETYLASE ENZYMES IN RESPONSE TO NERVE INJURY THAT PROMOTES HISTONE ACETYLATION LEADING TO PAIN INDUCTION. TREATMENT WITH HISTONE ACETYL TRANSFERASE INHIBITORS HAVE BEEN REPORTED TO RELIEVE CHRONIC PAIN BY BLOCKING THE UP-REGULATION OF CHEMOKINES AND CYCLOOXYGENASE-2, THE CRITICAL FACTORS ASSOCIATED WITH HISTONE ACETYLATION-INDUCED PAIN. THE PRESENT REVIEW DESCRIBES THE DUAL ROLE OF HISTONE ACETYLATION/DEACETYLATION IN DEVELOPMENT OR ATTENUATION OF NEUROPATHIC PAIN ALONG WITH THE UNDERLYING MECHANISMS. 2017 17 3341 22 HISTONE DEACETYLASE-2 IS INVOLVED IN STRESS-INDUCED COGNITIVE IMPAIRMENT VIA HISTONE DEACETYLATION AND PI3K/AKT SIGNALING PATHWAY MODIFICATION. EXPOSURE TO CHRONIC STRESS UPREGULATES BLOOD GLUCOCORTICOID LEVELS AND IMPAIRS COGNITION VIA DIVERSE EPIGENETIC MECHANISMS, SUCH AS HISTONE DEACETYLATION. HISTONE DEACETYLATION CAN LEAD TO TRANSCRIPTIONAL SILENCING OF MANY PROTEINS INVOLVED IN COGNITION AND MAY ALSO CAUSE LEARNING AND MEMORY DYSFUNCTION. HISTONE DEACETYLASE?2 (HDAC2) HAS BEEN DEMONSTRATED TO EPIGENETICALLY BLOCK COGNITION VIA A REDUCTION IN THE HISTONE ACETYLATION LEVEL; HOWEVER, IT IS UNKNOWN WHETHER HDAC2 IS INVOLVED IN THE COGNITIVE DECLINE INDUCED BY CHRONIC STRESS. TO THE BEST OF AUTHORS' KNOWLEDGE, THIS IS THE FIRST STUDY TO DEMONSTRATE THAT THE STRESS HORMONE CORTICOSTEROID UPREGULATE HDAC2 PROTEIN LEVELS IN NEURO?2A CELLS AND CAUSE CELL INJURIES. HDAC2 KNOCKDOWN RESULTED IN A SIGNIFICANT AMELIORATION OF THE PATHOLOGICAL CHANGES IN N2A CELLS VIA THE UPREGULATION OF HISTONE ACETYLATION AND MODIFICATIONS IN THE PHOSPHOINOSITIDE 3?KINASE/PROTEIN KINASE B SIGNALING PATHWAY. IN ADDITION, THE HDAC2 PROTEIN LEVELS WERE UPREGULATED IN 12?MONTH?OLD FEMALE C57BL/6J MICE UNDER CHRONIC STRESS IN VIVO. TAKEN TOGETHER, THESE FINDINGS SUGGESTED THAT HDAC2 MAY BE AN IMPORTANT NEGATIVE REGULATOR INVOLVED IN CHRONIC STRESS?INDUCED COGNITIVE IMPAIRMENT. 2017 18 5007 26 PERIPHERAL NERVE INJURY IS ASSOCIATED WITH CHRONIC, REVERSIBLE CHANGES IN GLOBAL DNA METHYLATION IN THE MOUSE PREFRONTAL CORTEX. CHANGES IN BRAIN STRUCTURE AND CORTICAL FUNCTION ARE ASSOCIATED WITH MANY CHRONIC PAIN CONDITIONS INCLUDING LOW BACK PAIN AND FIBROMYALGIA. THE MAGNITUDE OF THESE CHANGES CORRELATES WITH THE DURATION AND/OR THE INTENSITY OF CHRONIC PAIN. MOST STUDIES REPORT CHANGES IN COMMON AREAS INVOLVED IN PAIN MODULATION, INCLUDING THE PREFRONTAL CORTEX (PFC), AND PAIN-RELATED PATHOLOGICAL CHANGES IN THE PFC CAN BE REVERSED WITH EFFECTIVE TREATMENT. WHILE THE MECHANISMS UNDERLYING THESE CHANGES ARE UNKNOWN, THEY MUST BE DYNAMICALLY REGULATED. EPIGENETIC MODULATION OF GENE EXPRESSION IN RESPONSE TO EXPERIENCE AND ENVIRONMENT IS REVERSIBLE AND DYNAMIC. EPIGENETIC MODULATION BY DNA METHYLATION IS ASSOCIATED WITH ABNORMAL BEHAVIOR AND PATHOLOGICAL GENE EXPRESSION IN THE CENTRAL NERVOUS SYSTEM. DNA METHYLATION MIGHT ALSO BE INVOLVED IN MEDIATING THE PATHOLOGIES ASSOCIATED WITH CHRONIC PAIN IN THE BRAIN. WE THEREFORE TESTED A) WHETHER ALTERATIONS IN DNA METHYLATION ARE FOUND IN THE BRAIN LONG AFTER CHRONIC NEUROPATHIC PAIN IS INDUCED IN THE PERIPHERY USING THE SPARED NERVE INJURY MODAL AND B) WHETHER THESE INJURY-ASSOCIATED CHANGES ARE REVERSIBLE BY INTERVENTIONS THAT REVERSE THE PATHOLOGIES ASSOCIATED WITH CHRONIC PAIN. SIX MONTHS FOLLOWING PERIPHERAL NERVE INJURY, ABNORMAL SENSORY THRESHOLDS AND INCREASED ANXIETY WERE ACCOMPANIED BY DECREASED GLOBAL METHYLATION IN THE PFC AND THE AMYGDALA BUT NOT IN THE VISUAL CORTEX OR THE THALAMUS. ENVIRONMENTAL ENRICHMENT ATTENUATED NERVE INJURY-INDUCED HYPERSENSITIVITY AND REVERSED THE CHANGES IN GLOBAL PFC METHYLATION. FURTHERMORE, GLOBAL PFC METHYLATION CORRELATED WITH MECHANICAL AND THERMAL SENSITIVITY IN NEUROPATHIC MICE. IN SUMMARY, INDUCTION OF CHRONIC PAIN BY PERIPHERAL NERVE INJURY IS ASSOCIATED WITH EPIGENETIC CHANGES IN THE BRAIN. THESE CHANGES ARE DETECTED LONG AFTER THE ORIGINAL INJURY, AT A LONG DISTANCE FROM THE SITE OF INJURY AND ARE REVERSIBLE WITH ENVIRONMENTAL MANIPULATION. CHANGES IN BRAIN STRUCTURE AND CORTICAL FUNCTION THAT ARE ASSOCIATED WITH CHRONIC PAIN CONDITIONS MAY THEREFORE BE MEDIATED BY EPIGENETIC MECHANISMS. 2013 19 5579 31 ROLE OF MORPHINE, MIR-212/132 AND MU OPIOID RECEPTOR IN THE REGULATION OF BDNF IN ZEBRAFISH EMBRYOS. BACKGROUND: MORPHINE IS ONE OF THE FIRST-LINE THERAPIES FOR THE TREATMENT OF PAIN DESPITE ITS SECONDARY EFFECTS. IT MODIFIES THE EXPRESSION OF EPIGENETIC FACTORS LIKE MIRNAS. IN THE PRESENT STUDY, WE ANALYZED MIR-212 AND MIR-132 AND THEIR IMPLICATION IN MORPHINE EFFECTS IN THE ZEBRAFISH CENTRAL NERVOUS SYSTEM (CNS) THROUGH THE REGULATION OF BDNF EXPRESSION. METHODS: WE USED CONTROL AND KNOCK-DOWN ZEBRAFISH EMBRYOS TO ASSESS THE EFFECTS OF MORPHINE IN MIRNAS 212/132 AND MITOTIC OR APOPTOTIC CELLS BY QPCR, IMMUNOHISTOCHEMISTRY AND TUNEL ASSAY, RESPECTIVELY. BDNF AND TRKB WERE STUDIED BY WESTERN BLOT AND THROUGH A PRIMARY NEURON CULTURE. A LUCIFERASE ASSAY WAS PERFORMED TO CONFIRM THE BINDING OF MIRNAS 212/132 TO MECP2. RESULTS: MORPHINE EXPOSURE DECREASES MIR-212 BUT UPREGULATES MIR-132, AS WELLS AS BDNF AND TRKB, AND CHANGES THE LOCALIZATION OF PROLIFERATIVE CELLS. HOWEVER, BDNF EXPRESSION WAS DOWNREGULATED WHEN MIRNAS 212/132 AND OPRM1 WERE KNOCKED-DOWN. FURTHERMORE, WE PROVED THAT THESE MIRNAS INHIBIT MECP2 EXPRESSION BY BINDING TO ITS MRNA SEQUENCE. THE DESCRIBED EFFECTS WERE CORROBORATED IN A PRIMARY NEURON CULTURE FROM ZEBRAFISH EMBRYOS. CONCLUSIONS: WE PROPOSE A MECHANISM IN WHICH MORPHINE ALTERS THE LEVELS OF MIRNAS 212/132 INCREASING BDNF EXPRESSION THROUGH MECP2 INHIBITION. OPRM1 IS ALSO DIRECTLY INVOLVED IN THIS REGULATION. THE PRESENT WORK CONFIRMS A RELATIONSHIP BETWEEN THE OPIOID SYSTEM AND NEUROTROPHINS AND SHOWS A KEY ROLE OF MIR-212 AND MIR-132 ON MORPHINE EFFECTS THROUGH THE REGULATION OF BDNF PATHWAY. GENERAL SIGNIFICANCE: MIRNAS 212/132 ARE NOVEL REGULATORS OF MORPHINE EFFECTS ON CNS. OPRM1 CONTROLS THE NORMAL EXPRESSION OF BDNF. 2016 20 2266 27 EPIGENETIC PROGRAMMING OF MU-OPIOID RECEPTOR GENE IN MOUSE BRAIN IS REGULATED BY MECP2 AND BRG1 CHROMATIN REMODELLING FACTOR. THE PHARMACOLOGICAL ACTION OF MORPHINE AS A PAIN MEDICATION IS MEDIATED PRIMARILY THROUGH THE MU-OPIOID RECEPTOR (MOR). WITH FEW EXCEPTIONS, MOR IS EXPRESSED IN BRAIN REGIONS WHERE OPIOID ACTIONS TAKE PLACE. THE BASIS FOR THIS UNIQUE SPATIAL EXPRESSION OF MOR REMAINS UNDETERMINED. RECENTLY, WE REPORTED THAT DNA METHYLATION OF THE MOR PROMOTER PLAYS AN IMPORTANT ROLE IN REGULATING MOR IN P19 CELLS. IN THIS STUDY, WE SHOW THAT THE DIFFERENTIAL EXPRESSION OF MOR IN MICRODISSECTED MOUSE BRAIN REGIONS COINCIDES WITH DNA METHYLATION AND HISTONE MODIFICATIONS. MOR EXPRESSION COULD BE INDUCED BY A DEMETHYLATING AGENT OR A HISTONE DEACETYLASE INHIBITOR IN MOR-NEGATIVE CELLS, SUGGESTING THAT THE MOR GENE CAN BE SILENCED UNDER EPIGENETIC CONTROL. INCREASES IN THE IN VIVO INTERACTION OF METHYL-CPG-BINDING PROTEIN 2 (MECP2) WERE OBSERVED IN THE CEREBELLUM, IN WHICH THE MOR PROMOTER WAS HYPERMETHYLATED AND MOR EXPRESSION WAS THE LOWEST AMONG ALL BRAIN REGIONS TESTED. MECP2 IS ASSOCIATED CLOSELY WITH RETT SYNDROME, A NEURODEVELOPMENTAL DISORDER. WE ALSO ESTABLISHED NOVEL EVIDENCE FOR A FUNCTIONAL ROLE FOR MECP2'S ASSOCIATION WITH THE CHROMATIN-REMODELLING FACTOR BRG1 AND DNA METHYLTRANSFERASE DNMT1, SUGGESTING A POSSIBLE ROLE FOR MECP2 IN CHROMATIN REMODELLING DURING MOR GENE REGULATION. WE CONCLUDE THAT MOR GENE EXPRESSION IS EPIGENETICALLY PROGRAMMED IN VARIOUS BRAIN REGIONS AND THAT MECP2 ASSISTS THE EPIGENETIC PROGRAM DURING DNA METHYLATION AND CHROMATIN REMODELLING OF THE MOR PROMOTER. 2009